Adipotide
Peptidomimetic (FTPP; investigational) · Pre-filled pen
Adipotide is understood to home to the prohibitin marker on the endothelium of white adipose tissue (annexin-A2 is a separate adipose-vascular marker), then trigger a pro-apoptotic signal intended to disrupt the local blood supply. In animal studies this was associated with a loss of fat mass. For humans the approach remains investigational, and the pathway has not been confirmed in robust human trials.
Studied use areas
- Investigated in preclinical models for white-adipose-tissue mass reduction
- Studied as a vascular-targeting (anti-angiogenic) research approach to fat depots
- Explored as a tool to probe prohibitin signalling in adipose vasculature
Safety & status
- Preclinical only; no established human safety or efficacy data
- Animal studies reported renal (kidney) toxicity signals — a serious, compound-specific caution
- Use only under qualified physician supervision; not for use in pregnancy or breastfeeding
⚕ Clinical note: Adipotide is an investigational compound with no validated human data and known animal toxicity signals; it is not an approved therapy and any use is physician-supervised only, and nothing here is medical advice or a dosing guide.
Evidence: Grade D — no reliable human data; preclinical/animal evidence only · References: Kolonin et al., Nature Medicine 2004; Barnhart et al., Science Translational Medicine 2011; Daquinag et al., Trends in Pharmacological Sciences 2011
